美国食品药品监督管理局（FDA）表示，已获悉由强生公司旗下医疗科技部门及Cerenovus联合发布的信函，内容涉及主动撤回特定批次的Cerepak可解脱弹簧圈系统。该监管机构通过其官方网站披露了这一动态，凸显其对医疗器械安全性的持续关注。此次召回行动旨在及时消除潜在风险，保障患者用械安全。
美国食品药品监督管理局（FDA）表示，已获悉由强生公司旗下医疗科技部门及Cerenovus联合发布的信函，内容涉及主动撤回特定批次的Cerepak可解脱弹簧圈系统。该监管机构通过其官方网站披露了这一动态，凸显其对医疗器械安全性的持续关注。此次召回行动旨在及时消除潜在风险，保障患者用械安全。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.